Bekker said, “It will be worth it for each general company. “We are all hoping for the government [across sub-Saharan Africa] The general product is spent on the future budget, but it is actually dependent on donor funds. Even South Africa, which has a good GDP and supports 80 % of HIV responses, has already purchased an anti -retro virus for 6 million individuals every year. I think it will take several years to mobilize Lenacapavir’s money. ”
PEPFAR is currently focusing on the treatment of existing patients, and clinical trials such as Nomathemba Changiwana, a doctor of Desmond Tutu Health Foundation in South Africa, will begin to increase. In the fall, it will affect the African continent and other public health.
Changiwana spoke last week at KIGALI’s NCD Alliance Forum, explaining that the result of the new infection is entirely not related to HIV itself. Even those who have long -term HIV infections and even those who are controlled by anti -retro virus treatment are increasingly risk of metabolism such as hypertension, obesity and type 2 diabetes. Sahara south of Africa. “The HIV itself, like many anti -retro viruses, interferes with metabolism. “We are looking at chronic diseases like people living with HIV as in the general population.
This requires HIV processing for a new generation, and one concept is to use Lenacapavir as the basis of future combination therapy for those with viruses. Not only did it potentially alleviate some of the side effects of metabolism, but also hoped that this could lead to a treatment protocol that did not require an individual infected with HIV to take the drug every day.
Bekker said, “Various ideas have become weak. “Can we combine bimonthly cabotegravir with Lenacapavir injections for 6 months? [as a form of viral suppression]You will only come six times a year for treatment, and can you all inject? Is there a weekly retro virus pill in the work and can be combined with what can be injured for six months? It can be very freed for people. They always tell us how stigma is to take medicine every day. ”
But as expected to be funded by US resources, many of these studies are doubtful. “It’s not just pepfar. We are also worried about limiting restrictions on other kinds of research funds, such as the National Institute of Health. ” “It will just be more difficult to innovate and lead to progress.”
According to NGURE, other donors who can support global funds when they procure Lenacapavir will be able to leave, while BEKKER supports funds for HIV prevention and research through European institutions and supports donor funds for sources of scandinavia It is said that we are looking for new options. Japan and Australia. At the same time, she thought that last month’s events should be more preventive for African countries.
“Somehow, Africa should go one step further and contribute to the fight,” she said. “I think this is a big question. It was not necessarily a large amount of research and development, but in the future, it could contribute to this continent as needed. ”
At the same time, she is afraid that she can lose the unique opportunity provided by Lenacapavir without the same resources in the United States.
“It’s amazing that this happened as we had a breakthrough,” she says. “I will go back to us for many years and ultimately cost more for public health expenditures. Ultimately, if we can control this infectious disease faster, we will save more money and save life in the long run. ”
